Trastuzumab (TZB) and lapatanib (LAP) are biological antagonists targeting the HER2/neu receptors (also known as ERBB2 receptor) which have dramatically improved outcomes for HER2+ breast cancer (BC), a variant of the disease which is generally associated with a poor prognosis [1, 2]. Here, ERBB2 is linked to breast carcinoma.